MEETING AGENDA

The Future of Investigational Medicine: Utilizing Science to Optimize the Early Phase Oncology Clinical Trial Effort

March 23-26, 2023
The Banbury Center, Lloyd Harbor, New York

This meeting was organized by
Tobias Janowitz, Cold Spring Harbor Laboratory
Lillian Siu, Princess Margaret Cancer Centre

and generously funded by the
Cold Spring Harbor Laboratory – Northwell Health Affiliation

THURSDAY, MARCH 23

Afternoon Arrivals and check-in at Robertson House

6:00 pm Reception and dinner

FRIDAY, MARCH 24

7:15 am Breakfast

8:30 am **Welcome; Overview of Meeting, Goals**
Rebecca Leshan, The Banbury Center
Tobias Janowitz, Cold Spring Harbor Laboratory
Lillian Siu, Princess Margaret Cancer Centre
Robert Maki, Memorial Sloan Kettering Cancer Center

9:15 am **SESSION 1A: Trial Operations: Collaborations Across Disciplines, Sectors, and Institutions to Enable Early Phase Clinical Trials**
Sumithra Mandrekar, Mayo Clinic
S. Michael Rothenberg, Pfizer Inc.
Daniel Tan, National Cancer Centre Singapore

10:55 am **SESSION 1B: Trial Operations: Regulations and Cost-Effective Delivery of Early Phase Clinical Trials**
(v) Andrew Lo, Massachusetts Institute of Technology
Naranjargal Dashdorj, Onom Foundation
Ke Liu, Marengo Therapeutics

12:20 pm Luncheon

2:05 pm **SESSION 2: Incorporating New Technologies and Biomarkers into Clinical Trials**
Minetta Liu, Natera, Inc.
Lillian Siu, Princess Margaret Cancer Centre
Christina Yap, Institute of Cancer Research

3:45 pm **SESSION 3: What Are the Best Trial Endpoints, Especially if Remote Trial Technology Is Utilized?**
Shaalan Beg, Science 37
Neal Meropol, Flatiron Health
Christopher Hartshorn, National Institutes of Health (NIH)

5:00 pm **Day One Wrap-up**

6:00 pm Reception and dinner

SATURDAY, MARCH 25

7:45 am Breakfast

9:00 am **SESSION 4: Patient Inclusion and Trial Access**
Deborah Collyar, Patient Advocates In Research (PAIR)
Karen Mustian, Wilmot Cancer Institute
Elizabeth Fox, St. Jude Children's Research Hospital
Nyasha Chambwe, Feinstein Institutes for Medical Research

11:05 am **SESSION 5: Combinatorial Strategies in Drug Development – how to Nominate the Most Relevant and Truly Synergistic Combinations for Clinical Testing**
Helen Chen, National Cancer Institute Cancer Treatment Evaluation Program (CTEP)
Marcus Goncalves, Weill Cornell Medicine
Daniel King, Feinstein Institutes for Medical Research

12:30 pm Luncheon

2:20 pm **SESSION 6: Biological Validation in Early Phase Trials: Approaches and Implementation Strategies**
Keith T. Flaherty, Massachusetts General Hospital
Kurt A. Schalper, Yale University
Christophe Le Tourneau, Institut Curie
Yu Shyr, Vanderbilt University Medical Center
Tobias Janowitz, Cold Spring Harbor Laboratory

5:15 pm **Day Two Wrap-up**

6:00 pm Reception and dinner

SUNDAY, MARCH 26

7:45 am Breakfast

9:00 am **SESSION 7A: Summarizing & Consensus-Building**
Moderated Discussion: key concepts, recommendations

11:00 am **SESSION 7B: Meeting Output, Next Steps**
Moderated Discussion: planning output(s), responsibilities, next steps and timelines

12:00 pm Luncheon
1:30 pm Participant Departures

PARTICIPANTS

Victoria Aranda, Nature
Shaalan Beg, Science 37
Nyasha Chambwe, Feinstein Institutes for Medical Research
Helen Chen, National Cancer Institute Cancer Treatment Evaluation Program (CTEP)
Deborah Collyar, Patient Advocates In Research (PAIR)
Naranjargal Dashdorj, Onom Foundation
Keith T. Flaherty, Massachusetts General Hospital
Elizabeth Fox, St. Jude Children's Research Hospital
Marcus Goncalves, Weill Cornell Medicine
Christopher Hartshorn, National Institutes of Health (NIH)
Tobias Janowitz, Cold Spring Harbor Laboratory
Daniel King, Feinstein Institutes for Medical Research
Sam Kleeman, Cold Spring Harbor Laboratory
Christophe Le Tourneau, Institut Curie
Ke Liu, Marengo Therapeutics
Minetta Liu, Natera, Inc.
Andrew Lo, Massachusetts Institute of Technology
Robert Maki, Memorial Sloan Kettering Cancer Center
Sumithra Mandrekar, Mayo Clinic
Neal Meropol, Flatiron Health
Karen Mustian, Wilmot Cancer Institute
S. Michael Rothenberg, Pfizer Inc.
Kurt A. Schalper, Yale University
Yu Shyr, Vanderbilt University Medical Center
Lillian Siu, Princess Margaret Cancer Centre
Daniel Tan, National Cancer Centre Singapore
Andrew Whiteley, Cold Spring Harbor Laboratory
Christina Yap, Institute of Cancer Research